- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04805125
Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)
Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform
This study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative effectiveness and safety of approved SARS-CoV-2 vaccines in immunocompromised patients.
This platform will be tested in the frame of an exploratory pilot trial and a framework will be set up to conduct a larger, flexible, randomized controlled trial (RCT) to test approved SARS-CoV-2 vaccines to prevent SARS-CoV-2 infections.
The first sub-protocol for a pilot trial is to investigate the operability of a platform trial that is nested into two existing cohort studies and compare immune response, safety and clinical efficacy of the first two mRNA vaccines (Comirnaty® by Pfizer / BioNTech and COVID-19 mRNA Vaccine Moderna®, by Moderna) in immune compromised patients in the Swiss HIV and Swiss Transplant Cohort studies.
The second sub-protocol (observational study) is to collect a blood sample before the third vaccination and 8 weeks after vaccination to analyze an additional benefit of a third SARS-CoV-2 vaccine in these immunocompromised patients.
In the third sub-protocol (substudy-3; observational) we will recruit patients who have received m-RNA-1273.214 by Moderna in the frame of clinical routine. We will start a second arm of our observational study as soon as another bivalent mRNA vaccine (from Pfizer-BioNTech) has been approved by Swissmedic. We aim to compare the immunologic response and safety of the bivalent mRNA-1273.214 vaccine from Moderna among immunocompromised persons (persons living with HIV or kidney or lung transplant recipients) to the immunologic response of immunocompromised persons who received the bivalent mRNA vaccine from Pfizer-BioNTech.
Study Overview
Status
Conditions
Detailed Description
The aim of this study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative effectiveness and safety of approved SARS-CoV-2 vaccines in immunocompromised patients. Nesting this trial into cohorts with highly standardized data collection allows for a rapid, efficient and cost-saving trial conduct.
This platform will be tested in the frame of a pilot trial and a framework will be set up to conduct a larger, flexible, randomized controlled trial (RCT) to test approved SARS-CoV-2 vaccines to prevent SARS-CoV-2 infections.
The pilot study will primarily assess the functionality of the trial platform and early immunogenicity, efficacy and safety data. At a later stage, the platform might also be used to enlarge the pilot trial or to develop sub-protocols to deal with patients with no or insufficient immune response to Sars-CoV-2 vaccines.
Since January 12, 2021 two mRNA vaccines against Sars-CoV-2 by Pfizer / BioNTech (Comirnaty®) and COVID-19 mRNA Vaccine Moderna® by Moderna have been licensed in Switzerland and roll-out of vaccines has started
The first sub-protocol for a pilot trial is to investigate the operability of a platform trial that is nested into two existing cohort studies and compare immune response, safety and clinical efficacy of the first two mRNA vaccines (Comirnaty® by Pfizer / BioNTech and COVID-19 mRNA Vaccine Moderna®, by Moderna) in immune compromised patients in the Swiss HIV and Swiss Transplant Cohort studies.
In Switzerland, since October 2021 severely immunodeficient persons ≥ 12 years of age who have received two doses of an mRNA vaccine should receive a third dose of Comirnaty® or Spikevax® as part of the basic immunization, regardless of any antibody titer. Among all other immunocompromised patients a booster vaccination with an mRNA vaccine is recommended. These vaccines will be administered to patients from the SHCS and the STCS in the frame of clinical routine.
This second sub-protocol (observational study) is to collect a blood sample before the third vaccination and 8 weeks after vaccination to analyze an additional benefit of a third SARS-CoV-2 vaccine in these immunocompromised patients.
In the third sub-protocol (substudy-3; observational) we will recruit patients who have received m-RNA-1273.214 by Moderna in the frame of clinical routine. We will start a second arm of our observational study as soon as another bivalent mRNA vaccine (from Pfizer-BioNTech) has been approved by Swissmedic. We aim to compare the immunologic response and safety of the bivalent mRNA-1273.214 vaccine from Moderna (n=160) among immunocompromised persons (persons living with HIV or kidney or lung transplant recipients) to the immunologic response of immunocompromised persons who received the bivalent mRNA vaccine from Pfizer-BioNTech (n=80). Patients will be asked to provide blood sample at baseline (before receiving bivalent mRNA SARS-CoV-2 vaccine) and 4 weeks, 8 weeks, and 6 months after vaccination (see details in original study protocol below).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- University Hospital Basel
-
Bern, Switzerland, 3010
- University Hospital Bern
-
Lausanne, Switzerland, 1011
- University Hospital Lausanne CHUV
-
Zurich, Switzerland, 8091
- University Hospital Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- All patients registered with informed consent from participating cohorts aged ≥18 years
- Additional consent for participation in the specific sub-protocol trial
Inclusion criteria for pilot trial:
- All patients with either a chronic HIV infection or recipients of solid organs registered with informed consent from the SHCS and STCS cohorts aged ≥18 years
- Patients with solid organ transplantation of lungs or kidneys at least one month post-transplantation with a prednisone dose of 20mg or less.
- Covid-19 vaccination recommended by treating physician
Inclusion criteria for 2. sub protocol (observational study):
- Third covid-19 vaccination recommended by treating physician and administered in the frame of clinical routine
Inclusion criteria for 3. substudy.
- Patients receiving a new bivalent (Wuhan/Omicron BA.1) mRNA SARS-CoV-2 vaccine in the frame of clinical routine, according to the treating physician
Exclusion criteria:
- Acute symptomatic SARS-CoV-2 infection, influenza or other acute respiratory tract infection
- Known allergy or contra-indications for vaccines or any vaccine components
- Any emergency condition requiring immediate hospitalization for any condition
- Patients with previous PCR documented SARS-CoV-2 infection and, or documented antibodies less than 3 months prior to screening visit (day 0)
Exclusion criteria for pilot trial:
- Pregnancy
- Acute symptomatic SARS-CoV-2 infection, influenza or other acute respiratory tract infection
- Known allergy or contra-indications for vaccines or any vaccine components
- Any emergency condition requiring immediate hospitalization for any condition
- Patients with previous PCR documented SARS-CoV-2 infection and, or documented antibodies less than 3 months prior to randomisation
Patients with solid organ transplantation (lung or kidney) with the following conditions:
- Solid organ transplant recipients less than one month post-transplantation
- Solid organ transplant recipients with the use of T-cell/B-cell depleting agents in the last 3 months (i. e induction treatment in standard risk or high-risk immunological situation or rejection treatment).
- Solid organ transplant recipients with the need of pulse corticosteroids (>100mg prednisone or equivalent) in the last 1 month or who have received ATG or rituximab in the last 6 months
- Solid organ transplant recipients with the need of any kind of chemotherapy treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Moderna mRNA COVID-19 vaccine
The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart. ARM CLOSED |
intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
|
Active Comparator: Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine
Active: The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland. Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later. ARM CLOSED |
intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
immunological outcome: change in pan-Ig antibody response (pan-Ig anti-S1-RBD)
Time Frame: at baseline (day of vaccination) and three months after vaccination
|
A commercial immunoassay Elecsys® Anti-SARS-CoV-2 S for the in vitro quantitative determination of antibodies to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma is used.
This assay detects pan-Ig antibody response (pan-Ig anti-S1-RBD) and allows for a quantitative assessment of the serological response of the participants.
|
at baseline (day of vaccination) and three months after vaccination
|
immunological outcome: change in anti-Nucleocapsid (N) response
Time Frame: at baseline (day of vaccination) and three months after vaccination
|
Qualitative measurement of anti-Nucleocapsid (N) responses with Elecsys® Anti-SARS-CoV-2 N assay
|
at baseline (day of vaccination) and three months after vaccination
|
immunological outcome: change in SARS-CoV-2-binding antibodies
Time Frame: at baseline (day of vaccination) and three months after vaccination
|
SARS-CoV-2-binding antibody responses of the participants are assessed by analyzing the IgM, IgA and IgG responses to a wider range of SARS-CoV-2 proteins (S1, S2, RBD and N) using an in-house method (ABCORA).
The ABCORA test allows a parallel assessment of IgG, IgM and IgA reactivity.
|
at baseline (day of vaccination) and three months after vaccination
|
Number of participants with newly polymerase chain reaction (PCR)-confirmed asymptomatic COVID-19 infection
Time Frame: at any time point in within 48 weeks following randomisation (day of vaccination)
|
Number of participants with newly PCR-confirmed asymptomatic COVID-19 infection (identified by the presence of anti-SARS-CoV-2 nucleocapsid antibodies or Sars-Cov-2 PCR or rapid antigen test) and no related symptoms [(i.e.
fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea])
|
at any time point in within 48 weeks following randomisation (day of vaccination)
|
Number of participants with newly PCR-confirmed symptomatic COVID-19 infection
Time Frame: at any time point in within 48 weeks following randomisation (day of vaccination)
|
Number of participants with newly PCR-confirmed symptomatic COVID-19 infection with at least one of the following symptoms (i.e.
fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea
|
at any time point in within 48 weeks following randomisation (day of vaccination)
|
Number of participants with severe COVID-19 infection
Time Frame: at any time point in within 48 weeks following randomisation (day of vaccination)
|
Number of participants with severe COVID-19 infection with respiratory failure, evidence of shock (as diagnosed by a treating physician), clinically significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death
|
at any time point in within 48 weeks following randomisation (day of vaccination)
|
Clinical Outcome: COVID-19 burden of diseases (BOD)
Time Frame: within 48 weeks following randomisation (day of vaccination)
|
COVID-19 burden of diseases (BOD), a composite, will be scored as by using 0 for no COVID-19, 1 for non-severe COVID-19, and 2 for severe COVID-19.
|
within 48 weeks following randomisation (day of vaccination)
|
Duration of RCT set up (specific endpoint related to trial conduct feasibility)
Time Frame: one time assessment at baseline (from deciding which interventions will be tested until the first patient is randomised)
|
Duration of RCT set up (i.e.
time from deciding which interventions will be tested until the first patient is randomised).
|
one time assessment at baseline (from deciding which interventions will be tested until the first patient is randomised)
|
Time of patient recruitment from activation of first study site until 40 patients are randomised
Time Frame: one time assessment after approx. 3 months (from activation of first study site until 40 patients are randomised)
|
Time of patient recruitment from activation of first study site until 40 patients are randomised
|
one time assessment after approx. 3 months (from activation of first study site until 40 patients are randomised)
|
Time of patient recruitment from activation of first study site until 380 patients are randomised
Time Frame: one time assessment after approx. 3 months (from activation of first study site until 380 patients are randomised)
|
Time of patient recruitment from activation of first study site until 380 patients are randomised
|
one time assessment after approx. 3 months (from activation of first study site until 380 patients are randomised)
|
Patient consent rate
Time Frame: approx. 3 months
|
Patient consent rate (i.e.
proportion of patients giving informed consent out of approached eligible patients)
|
approx. 3 months
|
Proportion of missing data for all baseline variables from routinely collected cohort data
Time Frame: one time assessment at baseline
|
Proportion of missing data for all baseline variables from routinely collected cohort data
|
one time assessment at baseline
|
Proportion of missing data for all clinical outcomes
Time Frame: one time assessment after approx. 3 months
|
Proportion of missing data for all clinical outcomes from routinely collected cohort data and outcome data that is collected in the trial platform
|
one time assessment after approx. 3 months
|
SARS-CoV-2-specific antibodies
Time Frame: three months after vaccination
|
SARS-CoV-2-specific antibodies (using a pan-IgG antibody assay against the receptor binding domain (RBD) against the nP and spike 1 subunits)
|
three months after vaccination
|
SARS-CoV-2-specific titers
Time Frame: three months after vaccination
|
SARS-CoV-2-specific titers (using an in-house assay developed by the Institute of Medical Virology, University of Zurich which can detect multiple viral epitopes)
|
three months after vaccination
|
The proportion of patients with a positive antibody response to SARS-CoV-2 spike (S1) protein receptor binding domain in human serum or plasma assessed in the observational second sub- protocol
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
The proportion of patients with a positive antibody response to SARS-CoV-2 spike (S1) protein receptor binding domain in human serum or plasma assessed or plasma assessed in the observational second sub- protocol by the commercial immunoassay Elecsys Anti-SARS-CoV-2 S (Elecsys S) from Roche Diagnostics.
An antibody response will be considered as positive using the threshold ≥ 100 units/ml, predicting a protective immune response.
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients with a positive antibody response using SARS-CoV-2 spike (S1) Elecsys S by Roche in the observational second sub- protocol, using a threshold of ≥0.8 units/ml as defined by the manufacturer
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
The proportion of patients with a positive antibody response using SARS-CoV-2 spike (S1) Elecsys S by Roche in the observational second sub- protocol, using a threshold of ≥0.8 units/ml as defined by the manufacturer
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
The proportion of patients with a positive antibody response using antibody response using the Antibody CORonavirus Assay (ABCORA) 2 in the observational second sub- protocol
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
The proportion of patients with a positive antibody response using antibody response using the Antibody CORonavirus Assay (ABCORA) 2 in the observational second sub- protocol that assesses seropositivity by measuring specific IgG, IgA and IgM responses to SARS-CoV-2 receptor binding domains, S1, S2 and N16
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
The proportion of patients with neutralizing neutralization activity against the vaccine strain Wuhan-Hu-1 in the observational second sub- protocol
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
The proportion of patients with neutralizing neutralization activity against the vaccine strain Wuhan-Hu-1 in sera in the observational second sub- protocol defined as having an ABCORA sum S1 (sum of S1 signal over cut-off values of IgG, IgA, IgM) above the threshold of 17.
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Immune response (pan-Ig antibodies against the receptor binding domain (RBD) in the S1 subunit of the spike protein (pan-Ig anti-S1-RBD) of SARS-CoV-2 in the observational second sub- protocol
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Immune response (pan-Ig antibodies against the receptor binding domain (RBD) in the S1 subunit of the spike protein (pan-Ig anti-S1-RBD) of SARS-CoV-2 in the observational second sub- protocol
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Mean immune response of IgM, IgA and IgG to the subunit S1 using ABCORA in the observational second sub- protocol
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Mean immune response of IgM, IgA and IgG to the subunit S1 using ABCORA in the observational second sub- protocol
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Number of newly PCR-confirmed asymptomatic SARS-CoV-2 infection in the observational second sub- protocol
Time Frame: 8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Number of newly PCR-confirmed asymptomatic SARS-CoV-2 infection in the observational second sub- protocol
|
8 weeks (¨+/- 2 weeks) after 3. vaccination
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Outcome: number of local symptoms
Time Frame: during the first 7 days after vaccination
|
Any local symptom (redness or swelling or prolonged pain at injection side) limiting continuation of normal daily activities
|
during the first 7 days after vaccination
|
Safety Outcome: number of systemic symptoms
Time Frame: during the first 7 days after vaccination
|
Any systemic symptom (fever, generalized muscle or joint pain) limiting continuation of normal daily activities
|
during the first 7 days after vaccination
|
Safety Outcome: number of vaccine related symptoms
Time Frame: during the first 7 days after vaccination
|
Any vaccine related symptom leading to contacting a physician
|
during the first 7 days after vaccination
|
Number of participants with newly PCR-confirmed asymptomatic Covid-19 infection (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials)
Time Frame: at any time points within 48 weeks follow-up
|
Number of participants with newly PCR-confirmed asymptomatic Covid-19 infection (identified by the presence of anti-SARS-CoV-2 nucleocapsid antibodies, or SARS-CoV-" PCR or rapid antigen test) and no related symptoms [(i.e.
fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea])
|
at any time points within 48 weeks follow-up
|
Newly PCR-confirmed symptomatic Covid-19 infection (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials)
Time Frame: at any time points within 48 week follow-up
|
Newly PCR-confirmed symptomatic Covid-19 infection with at least one of the following symptoms (i.e.
fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea)
|
at any time points within 48 week follow-up
|
Number of participants with severe COVID-19 infection (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials)
Time Frame: at any time points within 48 week follow-up
|
Number of participants with severe COVID-19 infection with respiratory failure, evidence of shock (as diagnosed by a treating physician), clinically significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death
|
at any time points within 48 week follow-up
|
Covid-19 burden of diseases (BOD) (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials)
Time Frame: within 48 week follow-up
|
Covid-19 burden of diseases (BOD), a composite of the above endpoints.
The BOD will be scored as by using 0 for no COVID-19, 1 for non-severe COVID-19, and 2 for severe COVID-19
|
within 48 week follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Heiner C. Bucher, Prof. Dr. med., Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel
Publications and helpful links
General Publications
- Speich B, Chammartin F, Abela IA, Amico P, Stoeckle MP, Eichenberger AL, Hasse B, Braun DL, Schuurmans MM, Muller TF, Tamm M, Audige A, Mueller NJ, Rauch A, Gunthard HF, Koller MT, Trkola A, Briel M, Kusejko K, Bucher HC; Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clin Infect Dis. 2022 Aug 24;75(1):e585-e593. doi: 10.1093/cid/ciac169.
- Kusejko K, Chammartin F, Smith D, Odermatt M, Schuhmacher J, Koller M, Gunthard HF, Briel M, Bucher HC, Speich B; Swiss HIV Cohort Study; Swiss Transplant Cohort Study. Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients. BMC Infect Dis. 2022 Jul 28;22(1):654. doi: 10.1186/s12879-022-07621-x.
- Speich B, Chammartin F, Smith D, Stoeckle MP, Amico P, Eichenberger AL, Hasse B, Schuurmans MM, Muller T, Tamm M, Dickenmann M, Abela IA, Trkola A, Hirsch HH, Manuel O, Cavassini M, Hemkens LG, Briel M, Mueller NJ, Rauch A, Gunthard HF, Koller MT, Bucher HC, Kusejko K; study groups from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty(R) and COVID-19 mRNA Vaccine Moderna(R). Trials. 2021 Oct 21;22(1):724. doi: 10.1186/s13063-021-05664-0.
- Chammartin F, Kusejko K, Pasin C, Trkola A, Briel M, Amico P, Stoekle MP, Eichenberger AL, Hasse B, Braun DL, Schuurmans MM, Muller TF, Tamm M, Mueller NJ, Rauch A, Koller MT, Gunthard HF, Bucher HC, Speich B, Abela IA; and the Swiss HIV Cohort Study. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV. AIDS. 2022 Aug 1;36(10):1465-1468. doi: 10.1097/QAD.0000000000003246. Epub 2022 Jul 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-000593; me20Bucher
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunocompromised Patients
-
Groupe Hospitalier Paris Saint JosephCompletedImmunocompromised Patients and Non-immunosuppressed Patients at Risk With an Indication for Pneumococcal VaccinationFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingImmunocompromised PatientsFrance
-
Fundação Bahiana de InfectologiaCompletedSeverely Immunocompromised HIV PatientsBrazil
-
Children's Hospital Medical Center, CincinnatiAstellas Pharma IncTerminatedCancer | Immunocompromised | Bone Marrow TransplantUnited States
-
HepNet Study House, German LiverfoundationCompletedImmunocompromised | TransplantedGermany
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Respiratory Failure | Immunocompromised Patients
-
HepNet Study House, German LiverfoundationTerminated
-
University Hospital, LilleCompletedCritical Care | Immunocompromised HostFrance
-
Peking Union Medical College HospitalThe First Affiliated Hospital with Nanjing Medical University; National Natural... and other collaboratorsUnknownAcute Respiratory Failure | Immunocompromised Patients
-
First Affiliated Hospital of Guangxi Medical UniversitySecond Affiliated Hospital of Guangzhou Medical University; LiuZhou People's... and other collaboratorsRecruitingDiagnosis | Polymerase Chain Reaction | Immunocompromised Patients | Pneumocystis PneumoniaChina
Clinical Trials on Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
-
University of California, Los AngelesModernaTX, Inc.CompletedSARS-CoV-2 | Immunosuppression | Lung Transplant RecipientUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedSARS-CoV-2 InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedCovid19 | SARS-CoV2 InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...PPDCompleted
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI); University of Copenhagen; US... and other collaboratorsCompletedCovid19United States, Spain, Uganda, Nigeria, Singapore, Switzerland
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; Unity Health Toronto; Scarborough General... and other collaboratorsTerminatedCOVID-19 | Chronic Kidney DiseasesCanada
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Korea University Guro HospitalKorea University Anam Hospital; Ajou University School of Medicine; Korean Center... and other collaboratorsRecruitingCOVID-19 | Vaccine Adverse Reaction | Vaccine Immune ResponseKorea, Republic of
-
Centre Hospitalier Universitaire de Saint EtienneSanofi Pasteur, a Sanofi Company; Bioster, a.s.Completed
-
University Health Network, TorontoCompletedCovid19 | Vaccine Response Impaired | Immune SuppressionCanada